Informed Consent in Clinical Studies in the Republic of Srpska
Snežana Pantović
University of Montenegro , Montenegrohttps://orcid.org/0000-0003-1590-0020
Dijana Zrnić
Banja Luka University , Bosnia and Herzegovinahttps://orcid.org/0009-0002-0554-1917
Abstract
As human medicine is developing at a galloping pace, continuously offering new medical products, diagnostic methods and preventive programmes, there is almost no time gap between their creation and application in medical practice. All these biomedical achievements are primarily intended to improve public health and the patient’s quality of life and health. Hence, it is important to define potential risks, side effects, and unwanted outcomes when applying a medical product/treatment before integrating it into healthcare. Unlike any other product/treatment intended for human use, medical products/treatments require prior clinical testing on human subjects (sick or sound). The authors of this paper have restricted their scientific interest to the participant (human subject) of a clinical study as one of the core elements of a clinical investigation, representing at the same time its means and its aim. By analyzing relevant international as well as national legal rules and ethical principles of the Republic of Srpska related to the participation of humans in clinical studies, it will be concluded that the participants’ safety and right to self-determination, integrity, and autonomy manifested through their independent right to either consent or refuse to participate in a clinical study supersedes the interests of science or society. However, clinical trial-related statistical data obtained from randomly chosen healthcare institutions in the Republic of Srpska will show certain derogations from prescribed ethical policies. Considering this fact, the authors have paid special attention to thematising the ethicality of recruiting participants for a clinical study based on partial or no information related to the purpose, methods, potential risks and side effects of the investigation in the name of the greater good for humanity. Such practice has accentuated the discretionary powers of ethical review committees on the one side and the uncertainty of the right to informed consent on the other.
Keywords:
informed consent, clinical study, medical products/treatments, ethicality, public healthReferences
Beecher, Henry K. “Ethics and Clinical Research.” Bulletin of the World Health Organization 79, no. 4 (2001): 367–72.
Bhatt, Arun. “Evolution of Clinical Research: A History Before and Beyond James Lind.” Perspectives in Clinical Research 1, no. 1 (Jan-Mar 2010): 6–10. (Crossref)
Bojić, Denis, dir. The Faces of Lafora, 2017. https://www.youtube.com/watch?v=EP7OIQBN1jY.
Collier, Roger. “Legumes, Lemons and Streptomycin: A Short History of the Clinical Trial.” Canadian Medical Association Journal 180, no. 1 (2009): 23–4. (Crossref)
Grover, Surbhi, Melody Xu, Anuja Jhingran, Umesh Mahantshetty, Linus Chuang,e William Small, Jr., and David Gaffneyg. “Clinical Trials in Low and Middle-Income Countries – Successes and Challenges.” Gynecologic Oncology Reports 19 (2017): 5–9. (Crossref)
Harkness, Jon, Susan E. Lederer, and Daniel Winkler. “Laying Ethical Foundations for Clinical Research.” Bulletin of the World Health Organization 79, no. 4 (2001): 365–66.
Jalali, Rakesh, Angelica, Nogueira-Rodrigues, Arunangshu Das, Bhawna Sirohi, and Pankaj Kumar Panda. “Drug Development in Low - and Middle-Income Countries: Opportunity of Exploitation?.” American Society of Clinical Oncology Educational Book 42 (2022): 1–10. (Crossref)
Khoja, Adeel, Fizzah Kazim, and Naureen Akber Ali. “Barriers to Conducting Clinical Trials in Developing Countries.” The Ochsner Journal 19, no. 4 (2019): 294–5. (Crossref)
Kovačević, Ljiljana. “New Distribution of RS Budget: Planned Destruction of Healthcare, Culture, and Education.” Žurnal. November 6, 2023. Accessed Febryary 11, 2024. https://zurnal.info/clanak/plansko-unistavanje-zdravstva-kulture-i-obrazovanja/26383.
Nitschke, Felix, Saija J. Ahonen, Silvia Nitschke, Sharmistha Mitra, and Berge A. Minassian. “ Lafora Disease – From Pathogenesis to Treatment Strategies.” Nature Reviews Neurology 14 (2018): 606–17. https://doi.org/10.1038/s41582-018-0057-0. (Crossref)
Pantović, Snežana, and Dijana Zrnić. “Ethical, Clinical and Legal Aspects of Informed Consent in Montenegro, Republic of Srpska, Serbia and Croatia.” International Scientific Conference: Challenges and Perspectives of the Development of Legal Systems in the XXI Century – Conference Proceedings 1, no. 3 (2023): 115–33. https://doi.org/10.7251/NSTT12301115P.
Parihar, Rashmi, and Subramaniam Ganesh. “Lafora Progressive Myoclonus Epilepsy: Disease Mechanism and Therapeutic Attempts.” Journal of Biosciences 49, no. 22 (2024): 1–15. (Crossref)
Shin Lee, Hyoung. “Ethical Issues in Clinical Research and Publication.” Kosin Medical Journal 37, no. 4 (2022): 278–82, https://doi.org/10.7180/kmj.22.132. (Crossref)
Šolić, Ivana, Ana Stipičić, Ivančica Pavličević, Ana Marušić. “ Transparency and Public Accessibility of Clinical Trial Information in Croatia: How It Affects Patient Participation in Clinical Trials.” Biochemia Medica 27, no. 2 (2017): 259–69. https://doi.org/10.11613/BM.2017.027. (Crossref)
